Edition:
India

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.89USD
20 Jul 2018
Change (% chg)

$-0.06 (-6.77%)
Prev Close
$0.96
Open
$0.96
Day's High
$1.05
Day's Low
$0.85
Volume
135,216
Avg. Vol
22,917
52-wk High
$6.56
52-wk Low
$0.85

Chart for

About

ContraVir Pharmaceuticals, Inc. is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $48.36
Shares Outstanding(Mil.): 78.00
Dividend: --
Yield (%): --

Financials

BRIEF-Contravir Pharma Files For Series C Convertible Preferred Stock

* CONTRAVIR PHARMACEUTICALS FILES FOR SERIES C CONVERTIBLE PREFERRED STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF UP TO $20 MILLION - SEC FILING Source text: (https://bit.ly/2wUNyv5) Further company coverage:

19 May 2018

BRIEF-Contravir Pharmaceuticals Says Stockholders Approved Reverse Stock Split Of Common Stock

* CONTRAVIR PHARMACEUTICALS SAYS STOCKHOLDERS APPROVED REVERSE STOCK SPLIT OF COMMON STOCK AT RATIO WITHIN RANGE OF 1-FOR-5 AND 1-FOR-20 - SEC FILING Source text : [http://bit.ly/2p2XwU7] Further company coverage:

10 Mar 2018

BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population

* CONTRAVIR PHARMACEUTICALS ANNOUNCES TXL™ HAS BEEN GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF HBV IN A PEDIATRIC POPULATION Source text for Eikon: Further company coverage:

22 Feb 2018

BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA

* CONTRAVIR PHARMACEUTICALS REACHES AGREEMENT WITH THE FDA ON THE NDA PACKAGE FOR TXL™ LEVERAGING THE 505(B)(2) REGULATORY PATHWAY

12 Feb 2018

BRIEF-Contravir Pharma Completes Renal Impairment Study With TXL

* CONTRAVIR PHARMACEUTICALS COMPLETES RENAL IMPAIRMENT STUDY WITH TXL Source text for Eikon: Further company coverage:

06 Feb 2018

Earnings vs. Estimates